<DOC>
	<DOCNO>NCT01525563</DOCNO>
	<brief_summary>In India Duphaston approve widely use treatment progesterone deficiencies management dysmenorrhea , endometriosis , secondary amenorrhea , irregular cycle , dysfunctional uterine bleeding , pre-menstrual syndrome , threaten habitual abortion , infertility due luteal insufficiency , well part hormone replacement therapy . One Indian study report normalization cycle 91.6 % woman menstrual problem three cycle therapy dydrogesterone 10 mg give 11th 25th day menstrual cycle . The mean cycle duration dydrogesterone therapy study note 28.8 day , contrast 17.9 day ( polymenorrhea group ) 50.6 day ( oligomenorrhea group ) therapy . Furthermore , dydrogesterone also decrease amount duration menstrual bleeding study . However , limited data regard Duphaston 's role achieve cycle regularization post-marketing setting . Moreover , well-known effect Duphaston therapy persist cessation treatment whether persistent effect , , related duration Duphaston therapy . Hence , observational study , give ( base previous clinical study mention ) Duphaston play role menstrual irregularity treatment , goal tease possible implication treatment term treatment length response pattern .</brief_summary>
	<brief_title>Duphaston Cycle Regularization : A Post-marketing , Prospective , Multicenter , Observational Study</brief_title>
	<detailed_description>Primary objective : â€¢ To determine percentage patient report regular cycle ( defined cycle duration 21 35 day , inclusive ) end treatment period . Secondary objective : A . For patient : - To describe evolution cycle duration baseline end treatment assess mean cycle duration ( day ) baseline , separately polymenorrhea , ( i.e. , cycle duration &amp; lt ; 21 day ) oligomenorrhea ( i.e. , cycle duration &amp; gt ; 35 day ) group , end treatment . - To describe evolution duration menstrual bleeding baseline end treatment assess mean duration menstrual bleeding ( day ) baseline end treatment . - To describe evolution amount menstrual bleeding baseline end treatment , assess average number pad change per day baseline end treatment . - To describe evolution pain menstruation ( 11 point Likert Scale 0 mean pain 10 mean worst pain ) ) baseline end treatment , assess mean standard deviation pain score baseline end treatment . - To describe overall patient satisfaction ( 5 point Clinical Global Impression Severity scale , 1 = dissatisfy , 2 = dissatisfy , 3 = somewhat satisfy , 4 = satisfy , 5 = satisfy ) end treatment , assess percentage patient category end treatment . - To describe overall clinical response ( 7 point Clinical Global Impression Severity scale , 1 = Normal , ill , 2 = Borderline mentally ill , 3 = Mildly ill , 4 = Moderately ill , 5 = Markedly ill , 6 = Severely ill , 7 = Most extremely ill ) ) end treatment assess percentage patient category end treatment . B . For patient achieve regular cycle end treatment : - To determine percentage patient still experience regular cycle ( i.e. , duration 21-35 day , inclusive ) end follow period , total number patient achieved cycle regularization end treatment period . - To determine median time relapse ( defined cycle duration &amp; lt ; 21 day &amp; gt ; 35 day ) follow period , patient achieve regular cycle end treatment , use Kaplan Meier 's method graphically plot time cessation treatment versus percentage patient still regular cycle . - To determine correlation treatment duration ( number cycle Duphaston treatment receive ) persistence effect ( number month regular cycle maintain cessation Duphaston therapy ) , use linear regression analysis model . - To describe evolution duration menstrual bleeding cessation treatment end follow , assess mean duration menstrual bleeding ( day ) end treatment end follow . - To describe evolution amount menstrual bleeding cessation treatment end follow , assess average number pad change per day end treatment end follow . - To describe evolution pain menstruation ( 11 point Likert Scale 0 mean pain 10 mean worst pain ) cessation treatment end follow , assess mean standard deviation pain score end treatment end follow .</detailed_description>
	<mesh_term>Dydrogesterone</mesh_term>
	<criteria>Inclusion Criteria Women age 18 year old Suffering irregular menstrual cycle least 3 month physician decides prescribe Duphaston , accordance locally approve package insert Patients willing sign write authorization provide data study Exclusion Criteria Patients known hypersensitivity active ingredient excipients Patients know suspected progesteronedependent neoplasms Patients vaginal bleed unknown etiology Patients take oral contraceptive Pregnant lactate patient Any condition precludes use Duphaston particular patient , accordance contraindication , precaution special warning list locally approve package insert ( example , patient history liver disease , porphyria depression ) Patients willing sign write authorization data release consent form</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Duphaston Study</keyword>
</DOC>